Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 2/20 | 0.49 |
| ▸ | CMA1 | P23946 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4447502 | 0.84 | CTSG (0.49) | CTSGCMA1POLBARPTGDR2 | |
| SCHEMBL4451685 | 0.82 | SLC12A2 (0.50) | CTSGCMA1L3MBTL1PTGDR2HCRTR1 | |
| SCHEMBL5622354 | 0.79 | CMA1 (0.58) | CTSGCMA1L3MBTL1PTGDR2HCRTR1 | |
| SCHEMBL4452678 | 0.77 | CTSG (0.49) | CTSGCMA1POLBPDPK1HCRTR1 | |
| SCHEMBL7034397 | 0.74 | PTGDR2 (0.53) | CTSGCMA1ARPTGDR2TP53 | |
| SCHEMBL5621422 | 0.74 | CMA1 (0.66) | CTSGCMA1POLBARL3MBTL1 | |
| SCHEMBL5106157 | 0.73 | PTGDR2 (0.71) | POLBARPTGDR2PDPK1MEN1 | |
| SCHEMBL5622412 | 0.73 | CTSG (0.57) | CTSGCMA1POLBARL3MBTL1 | |
| SCHEMBL5623074 | 0.72 | CTSG (0.59) | CTSGCMA1POLBL3MBTL1PTGDR2 | |
| SCHEMBL7035261 | 0.71 | POLB (0.46) | POLBARL3MBTL1PTGDR2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054319-A1 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders | MICROBIA, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20030083315-A1 | Human chymase inhibitors | TEIJIN LIMITED (JP) | 2003-05-01 | — | — | US | disclosed |
| EP-1167360-A9 | HUMAN CHYMASE INHIBITORS | TEIJIN LIMITED (JP) | 2002-05-15 | — | — | EP | disclosed |
| EP-1167360-A1 | HUMAN CHYMASE INHIBITORS | TEIJIN LIMITED (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083315-A1 | Human chymase inhibitors | CMA1, CTRL, CPA4 | CTSG 204/4885CMA1 1/4885POLB 2758/4885 |
| US-20090054319-A1 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders | PTGIS, PTGIR, GRPR | CTSG 1249/4885CMA1 313/4885POLB 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.